CpG 2216
Alternative Names: CpG ODN 2216; Research programme: CpG oligonucleotides - Coley Pharmaceutical GroupLatest Information Update: 03 Apr 2003
At a glance
- Originator Coley Pharmaceutical Group
- Class Adjuvants; Antineoplastics
- Mechanism of Action Immunomodulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 03 Apr 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
- 22 Aug 2001 New profile
- 22 Aug 2001 Preclinical development for Cancer in USA (Unknown route)